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Background: Genetic modiﬁers like mannose binding lectin (MBL2) gene inﬂuence
occurrence and severity of CF associated liver disease (CFLD). Variants of MBL
genotypes encode low serum levels of MBL protein.
Aim study was to assess MBL serum levels in CFLD patients (pts), comparing to
CF pts without liver disease.
Methods: Study was performed in Pediatric II Department and National Cystic
Fibrosis Centre Romania, during May-September 2007. 35 CF children aged 2−18
years, presented to annual assessment were evaluated. We consider 3 groups of
patients, as follows: group 1 (21 CFLD patients), group 2 (11 pts CF no CFLD),
group 3 (15 controls). Groups were age matched. Patients associating diseases who
inﬂuence MBL level were excluded. MBL assay procedure was performed using
MBL Oligomer ELISA kit. Data were statistically analyzed with ANOVA.
Results: 46% CFLD pts were MBL deﬁcient. Among CFLD pts (group 1) MBL
average was 2061.99 ng/ml, half of control’s average (p = 0.001). Group 2 had an
average lower with 13% comparing to controls.
Conclusions: Lower MBL average in CFLD patients sustains that MBL deﬁciency
is associated factor for CFLD. Increased MBL levels in CFLD patients could be
resultant of increase growth hormone levels in childhood or predominance of “wild”
MBL2 genotype in our patients. Longitudinal evaluation of MBL levels and MBL2
genotyping would be useful to identify the patients predisposed to develop CFLD.
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Background: Our aim was to study the volume of the pancreas in adult cystic
ﬁbrosis (CF) patients with and without CF related diabetes (CFRD) using Magnetic
Resonance Imaging (MRI).
Patients and Methods: We prospectively studied 30 pancreatic insufﬁcient CF
patients, mean age 25.9 (17−42 years). Diagnosis of CF was established by clinical
symptoms, sweat tests and presence of known CF mutations. 14 patients had CFRD
and 16 patients were non diabetic according to World Health Organization criteria.
None of the non diabetics had impaired oral glucose tolerance tests and CFRD
patients were receiving insulin replacement therapy at the time of the study. MRI
scans were acquired using T1 weighted fat suppression sequences and assessed by
an examiner (MC) unaware of patients’ diabetic status.
Results: The 2 groups were matched for age and gender. There were no differences
in body mass index or exocrine pancreatic function as assessed by the requirement
of oral lipase. CFRD patients had lower FEV1 and FVC, but this did not attain
statistical signiﬁcance. The pancreas was visible by MRI in only 4 of 14 (28.6%)
patients with CFRD and in 5 of 16 (31.3%) patients without CFRD. In a total of
21 of 30 (70%) patients with and without CFRD the pancreas was not detected by
MRI.
Conclusions: This is the ﬁrst study to show that the pancreas is not measurable
as an entity in the majority of CF patients irrespective of their diabetic status. The
fact that the pancreas was not visible by MRI even in patients without clinical or
biochemical evidence of diabetes raises the question as to why not all patients with
non visible pancreas are diabetics.
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The applicability of acid steatocrit (AS) in the assessment of fecal fat losses has
been assessed with contradictory results. In the present study, we have aimed to
determine the role of AS in in CF patients with mild (<10g/d) or no steatorrhea.
Material & methods: The study comprised 45 CF patients aged 7 to 18 years. In all
subjects fecal fat concentration (FFC) and excretion (FFE) in day stool collection
was assessed as well as AS values in a single stool sample were determined.
Results: 130 triple results (FFC, FFE, AS) were available for the analysis. The range
of values (median; mean±SEM) of FFE, FFC and AS were as follow: 0.8−9.9 g/day
(4.2%; 4.9±0.2), 0.7−30.6 g/g (4.0; 6.2±0.6) and 4.0−35.0% (10.0; 13.1±0.7). AS
correlated both with FFE (r< 0.203, p< 0.021) and FFC values (r< 0.224, p< 0.01).
The correlations, although statistically signiﬁcant, were very weak. The speciﬁcity
and sensitivity of AS in the determination of abnormal FFC were low: 59.2% and
54.0% for the cut-off level of 10% and 31.5% and 84.2% for the cut-off level of
20%. Similarly, low PPV and NPV values were observed (47.8% and 65.1% for a
lower cut-off level and 58.6% and 63.4% for a higher cut-off level).
Conclusions: Acid steatocrit does not reﬂect fecal fat excretion in cystic ﬁbrosis
patients with mild or no steatorrhea. Moreover, its applicability in the assessment
of fecal fat concentration in this subgroup of patients has no practical value.
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Steatosis and an inﬂammatory, reactive-ﬁbrosing process leads to focal and multi-
lobular biliary cirrhosis in cystic ﬁbrosis (CF). Serum adiponectin (AD) is elevated
in CF patients.
Aim: To investigate any correlation between the degree of liver involvement and
serum AD.
Methods: Hepatic ultrasound was performed in 21 CF patients and 10 controls.
Liver involvement was demonstrated in 12 CF patients, who underwent percuta-
neous liver biopsy with the biopsy needle directed to the site of the lesion with CT
scan. The grading scale of CF-related liver histology was: 1 = normal, 2 = steatosis,
3 = steatosis + inﬂammatory reaction, 4 = inﬂammatory reaction + ﬁbrosis (focal
biliary cirrhosis) and 5 = multilobular biliary cirrhosis. Five groups were studied:
Group A = Controls (10, mean age 13.50 yrs); Group B = CF patients having no
liver disease (9, mean age 20 years); Group C = 4 CF patients – grade 2 or 3;
Group D = 4 CF patients – grade 4; and Group E = 4 CF patients – grade 5. The
mean age of CF-LD patients was 14.50 yrs.
Results: AD was signiﬁcantly different (p = 0.005) between CF patients having liver
involvement (mean AD 10.59mg/ml) and those having normal liver (mean AD
7.36mg/ml) as well as controls (mean AD 5.61mg/ml). Furthermore, signiﬁcant
correlation was demonstrated (one way ANOVA, p = 0.000) between the grading
of liver involvement and AD (control = 5.61, grade 1 = 7.36, grade 2+3 = 7.41,
grade 4 = 8.38, grade 5 = 15.49 (mg/ml).
Conclusion: Adiponectin measurement may be a screening test for the assessment
of the degree of the inﬂammatory, reactive ﬁbrosing process in the liver of CF
patients.
